Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Mechanisms of distraction in acute pain perception and modulation.

Birnie KA, Chambers CT, Spellman CM.

Pain. 2017 Jun;158(6):1012-1013. doi: 10.1097/j.pain.0000000000000913. Review. No abstract available.

PMID:
28514252
2.

Urticarial skin rash, fever, and arthralgia: a rare case of Schnitzler's syndrome.

Thummala H, Alshurbaji E, Onteddu NK, Reddy A, Spellman C, Ahmed Y.

Scand J Rheumatol. 2015;44(5):428-9. doi: 10.3109/03009742.2015.1033008. Epub 2015 May 20. No abstract available.

PMID:
25992683
4.

Effect of inpatient electroencephalography on clinical decision making.

Harmon LA, Craddock M, Jones E, Spellman CW, Loveman DM.

J Am Osteopath Assoc. 2013 Dec;113(12):891-6. doi: 10.7556/jaoa.2013.067.

PMID:
24285031
5.

Effect of vitamin D replacement on insulin sensitivity in subjects with vitamin D deficiency.

Simha V, Mahmood M, Ansari M, Spellman CW, Shah P.

J Investig Med. 2012 Dec;60(8):1214-8. doi: 10.2310/JIM.0b013e3182747c06.

PMID:
23111651
6.

Expression of trisomic proteins in Down syndrome model systems.

Spellman C, Ahmed MM, Dubach D, Gardiner KJ.

Gene. 2013 Jan 10;512(2):219-25. doi: 10.1016/j.gene.2012.10.051. Epub 2012 Oct 26.

PMID:
23103828
7.

Controversies in prediabetes: do we have a diagnosis?

Hollander P, Spellman C.

Postgrad Med. 2012 Jul;124(4):109-18. doi: 10.3810/pgm.2012.07.2562. Review.

PMID:
22913899
8.

Abnormal glucose metabolism in Hispanic parents of children with acanthosis nigricans.

Urrutia-Rojas X, McConathy W, Willis B, Menchaca J, Luna-Hollen M, Marshall K, Lacko A, Spellman C.

ISRN Endocrinol. 2011;2011:481371. doi: 10.5402/2011/481371. Epub 2011 Dec 25.

9.

Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.

Spellman CW.

J Am Osteopath Assoc. 2012 Jan;112(1 Suppl 1):S7-15. Review.

PMID:
22267302
10.

Common patient concerns about the use of glucagon-like peptide-1 receptor agonists in diabetes mellitus management.

Freeman JS, Gavin JR 3rd, Spellman CW.

J Am Osteopath Assoc. 2012 Jan;112(1 Suppl 1):S22-4.

PMID:
22267301
11.

Diabetes--it's the basics that count.

Spellman CW.

J Am Osteopath Assoc. 2011 May;111(5 Suppl 4):S2, 2 p preceding S2. No abstract available.

PMID:
21834206
12.

Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations.

Harmon L, Chilton RJ, Spellman C.

Postgrad Med. 2011 Mar;123(2):7-17. doi: 10.3810/pgm.2011.03.2258. Review.

PMID:
21474888
13.

Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.

Spellman CW.

J Am Osteopath Assoc. 2011 Feb;111(2 Suppl 1):eS10-4. Review.

PMID:
21389294
14.

Improving outcomes in patients with type 2 diabetes mellitus: practical solutions for clinical challenges.

Gavin JR 3rd, Stolar MW, Freeman JS, Spellman CW.

J Am Osteopath Assoc. 2010 May;110(5 Suppl 6):S2-14; quiz S15-6.

PMID:
20554501
15.

Pathophysiology of type 2 diabetes: targeting islet cell dysfunction.

Spellman CW.

J Am Osteopath Assoc. 2010 Mar;110(3 Suppl 2):S2-7. Review.

PMID:
20382838
16.

Augmentative and alternative communication intervention in children with traumatic brain injury and spinal cord injury.

Fager S, Spellman C.

J Pediatr Rehabil Med. 2010;3(4):269-77. doi: 10.3233/PRM-2010-0142.

PMID:
21791861
17.

Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors.

Spellman CW.

J Am Osteopath Assoc. 2009 May;109(5 Suppl):S8-S13. Review.

PMID:
19451256
18.

Management of progressive type 2 diabetes: role of insulin therapy.

Chemitiganti RR, Spellman CW.

Osteopath Med Prim Care. 2009 Jul 2;3:5. doi: 10.1186/1750-4732-3-5.

19.

Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss.

Spellman CW.

J Am Osteopath Assoc. 2008 May;108(5 Suppl 3):S20-7.

PMID:
18519839
20.

Islet cell dysfunction in progression to diabetes mellitus.

Spellman CW.

J Am Osteopath Assoc. 2007 May;107 Suppl:S1-5. Review.

PMID:
17724012
21.

Insulin therapy for maximal glycemic control in type 2 diabetes mellitus.

Spellman CW.

J Am Osteopath Assoc. 2007 Jul;107(7):260-9. Review.

PMID:
17682113
22.

Should all diabetic patients receive statins?

Garcia PJ, Spellman CW.

Curr Atheroscler Rep. 2006 Jan;8(1):13-8. Review.

PMID:
16455009
23.

Cardiovascular risk factors in Mexican-American children at risk for type 2 diabetes mellitus (T2DM).

Urrutia-Rojas X, Menchaca J, Wadley W, Ahmad N, Lacko A, Bae S, Spellman C, Kudchodkar B, Kudolo G, McConathy W.

J Adolesc Health. 2004 Apr;34(4):290-9.

PMID:
15040998
24.

Management of diabetes in the real world: tight control of glucose metabolism.

Spellman CW.

J Am Osteopath Assoc. 2003 Aug;103(8 Suppl 5):S8-13. Review.

PMID:
12962204
25.

Strategies for optimizing lipid treatment outcomes.

Spellman CW.

J Am Osteopath Assoc. 2003 Jan;103(1 Suppl 1):S12-5.

PMID:
12572625
26.

Combination therapy for dyslipidemia.

Spellman CW.

J Am Osteopath Assoc. 2003 Jan;103(1 Suppl 1):S9-11.

PMID:
12572624
27.

A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection.

Spellman CW, Matty KJ, Weis SE.

AIDS. 1998 Jan 22;12(2):191-5.

PMID:
9468368
28.

New methods for evaluating vision.

Cress PJ, Spellman CR.

ASHA. 1991 Nov;33(11):40-1, 60. No abstract available.

PMID:
1741792
29.

Peripheral blood mononuclear-cell interleukin-2 production, receptor generation and lymphokine-activated cytotoxicity in inflammatory bowel disease.

Ming RH, Atluru D, Spellman CW, Imir T, Goodwin JS, Strickland RG.

J Clin Immunol. 1987 Jan;7(1):59-63.

PMID:
3104392
30.

Low dose irradiation permits immunization of A/J mice with subimmunogenic numbers of SaI cells.

Anderson RE, Tokuda S, Williams WL, Spellman CW.

Br J Cancer. 1986 Sep;54(3):505-9. No abstract available.

31.

Health care organizations--successful, surviving, or swallowed up?

Spellman CM, Devin ME, Hughes RF.

Hosp Mater Manage Q. 1986 May;7(4):72-9. No abstract available.

PMID:
10276221
32.

The Parsons visual acuity test for screening children 18 to 48 months old.

Cibis GW, Maino JH, Crandall MA, Cress P, Spellman CR, Shores RE.

Ann Ophthalmol. 1985 Aug;17(8):471-5, 478.

PMID:
4051380
33.
34.

Noncycloplegic vs cycloplegic retinoscopy in pre-school children.

Maino JH, Cibis GW, Cress P, Spellman CR, Shores RE.

Ann Ophthalmol. 1984 Sep;16(9):880-2.

PMID:
6508104
35.

Lymphokines in autoimmunity: relationship between interleukin-2 and interferon-gamma production in systemic lupus erythematosus.

Sibbitt WL Jr, Kenny C, Spellman CW, Ley KD, Bankhurst AD.

Clin Immunol Immunopathol. 1984 Aug;32(2):166-73.

PMID:
6428789
36.

Cross-reactive transplantation antigens between UV-irradiated skin and UV-induced tumors.

Spellman CW, Daynes RA.

Photodermatol. 1984 Aug;1(4):164-9.

PMID:
6397735
37.

Impaired natural killer cell function in systemic lupus erythematosus. Relationship to interleukin-2 production.

Sibbitt WL Jr, Likar L, Spellman CW, Bankhurst AD.

Arthritis Rheum. 1983 Nov;26(11):1316-20.

PMID:
6605749
38.

The school nurse's role in vision screening for the difficult-to-test student.

Johnson JL, Spellman CR, Cress PJ, Sizemore AC, Shores RE.

J Sch Health. 1983 Aug;53(6):345-50.

PMID:
6225903
39.

Establishment of a continuous T cell line capable of suppressing anti-tumor immune responses in vivo.

Roberts LK, Spellman CW, Warner NL.

J Immunol. 1983 Jul;131(1):514-9.

PMID:
6223081
40.

Ultraviolet light-induced suppression of antigen presentation.

Spellman CW, Tomasi TB.

J Clin Immunol. 1983 Apr;3(2):105-10.

PMID:
6406536
41.

Low dose radiosensitivity of alloimmune cytotoxic T cells.

Spellman C, Anderson RE.

J Exp Med. 1982 Jun 1;155(6):1858-63.

42.

Ultraviolet irradiation, tumors, and suppressor T cells.

Spellman CW, Daynes RA.

Hum Pathol. 1981 Jun;12(6):489-91. No abstract available.

PMID:
6168557
43.

Ultraviolet light, tumors, and suppressor T cells.

Spellman CW, Daynes RA.

Hum Pathol. 1981 Apr;12(4):299-301. No abstract available.

PMID:
6165667
44.

Modulation of immunoregulatory responses directed toward various tumor antigens within hosts possessing distinct immunologic potentials.

Roberts LK, Spellman CW, Daynes RA.

J Immunol. 1980 Aug;125(2):663-72. No abstract available.

PMID:
6156212
45.

Skin cancer after PUVA treatment for psoriasis.

Spellman CW.

N Engl J Med. 1979 Sep 6;301(10):554-5. No abstract available.

PMID:
460313
46.

Phenotypic and physical characteristics of the lymphoid cells involved in the immunity to syngeneic UV-induced tumors.

Daynes RA, Schmitt MK, Roberts LK, Spellman CW.

J Immunol. 1979 Jun;122(6):2458-64. No abstract available.

PMID:
312869
47.

Flow cytometry analysis of murine B cell lymphoma differentiation.

Warner NL, Daley MJ, Richey J, Spellman C.

Immunol Rev. 1979;48:197-243. Review. No abstract available.

PMID:
161906
48.

Ultraviolet light induced murine suppressor lymphocytes dictate specificity of anti-ultraviolet tumor immune responses.

Spellman CW, Daynes RA.

Cell Immunol. 1978 Jun;38(1):25-34. No abstract available.

PMID:
667957
49.

Properties of ultraviolet light-induced suppressor lymphocytes within a syngeneic tumor system.

Spellman CW, Daynes RA.

Cell Immunol. 1978 Mar 15;36(2):383-7. No abstract available.

PMID:
630612
50.

Immunoregulation by ultraviolet light-III. Enhancement of suppressor cell activity in older animals.

Spellman CW, Daynes RA.

Exp Gerontol. 1978;13(3-4):141-6. No abstract available.

PMID:
308461

Supplemental Content

Loading ...
Support Center